Trandolapril and Acarbose: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 10, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Acarbose
Trandolapril
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What this means for you: Acarbose (Precose) helps lower your blood sugar, and trandolapril (Mavik) is a blood pressure medicine that belongs to a group called ACE inhibitors. When taken together, there may be a slightly higher chance that your blood sugar drops too low. That is called hypoglycemia, and it can make you feel shaky, sweaty, dizzy, or confused.
The good news is this is based on theory, not strong proof, and your care team can manage it easily. They may simply check your blood sugar a little more often. Please don't stop either medicine on your own, and let your pharmacist or doctor know if you feel any low-sugar symptoms.
Interaction: ACE inhibitors such as trandolapril may enhance the glucose-lowering effect of antidiabetic agents including acarbose, increasing hypoglycemia risk. Neither drug is a prodrug relevant here; the effect is pharmacodynamic (additive), not a CYP-mediated PK change.
- Direction: increased antidiabetic effect / potential hypoglycemia
- Mechanism: unknown; possibly improved insulin sensitivity with ACE inhibition
- Evidence: theoretical; a self-controlled case series found no increase in serious hypoglycemia with insulin secretagogues, possible exception glimepiride
- Onset: unspecified
Management: More frequent glucose monitoring during therapy and after ACE inhibitor withdrawal; adjust antidiabetic therapy as clinically indicated.
What happens
An increased risk of hypoglycemia
Interaction Deep Dive
When ACE inhibitors are given together with antidiabetic medications, the likelihood of hypoglycemia may rise 134. Should such combined therapy be necessary, glucose levels should be checked more often, both while treatment continues and following discontinuation of an ACE inhibitor 2. Modifications to insulin dosing might likewise be required 13. Findings from a self-controlled case series indicate that combining ACE inhibitors with insulin secretagogues does not correlate with higher rates of serious hypoglycemia, though glimepiride may be a potential exception 5.
Why it happens (mechanism)
Unknown
How to manage this interaction
How to manage this interaction: The two medicines can usually be taken together safely with a little extra attention.
- Keep taking both exactly as prescribed unless your prescriber tells you otherwise.
- Your care team may check your blood sugar more often, both while you are on trandolapril and for a while after stopping it.
- Your diabetes medication dose may need to be adjusted and individualized by your care team.
- Learn the signs of low blood sugar (shakiness, sweating, dizziness, confusion) and know how to treat it quickly.
Talk with your pharmacist or doctor if you notice frequent low readings or symptoms.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) A self-controlled case series examined Medicare claims data drawn from 5 states spanning 1999 to 2011 to assess the simultaneous use of ACE inhibitors alongside insulin secretagogues (glimepiride, glipizide, glyburide, nateglinide, and repaglinide) or metformin (used as a negative control). The endpoint assessed was hospital presentation for serious hypoglycemia. Throughout the observation period, the counts of serious hypoglycemic events were 8159, 14,353, 11,129, 1595, 2901, and 32,639 for glimepiride, glipizide, glyburide, nateglinide, repaglinide, and metformin, respectively. The confounder-adjusted rate ratio (RR) showed no significant increase for glipizide, glyburide, repaglinide, or metformin, but was modestly raised for glimepiride (RR, 1.23; 95% CI, 1.11 to 1.37) and modestly lowered for nateglinide (RR, 0.73; 95% CI, 0.56 to 0.96). Aside from glimepiride, these findings indicate that concurrent use of an ACE inhibitor and insulin secretagogues was not linked to a heightened risk of serious hypoglycemia 5.
Common questions
Can I take Trandolapril and Acarbose together?
Taking acarbose with trandolapril may slightly raise the chance of low blood sugar, so your team may check your glucose more often. Keep taking both as prescribed and report any low-sugar symptoms. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Trandolapril and Acarbose interaction?
It is rated moderate. Can be significant — usually manageable with monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Trandolapril and Acarbose interaction managed?
How to manage this interaction: The two medicines can usually be taken together safely with a little extra attention. Keep taking both exactly as prescribed unless your prescriber tells you otherwise. Your care team may check your blood sugar more often, both while you are on trandolapril and for a while after stopping it. Your diabetes medication dose may need to be adjusted and individualized by… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Trandolapril or Acarbose need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there anything you'd monitor while I'm on both?
References (5)
- Product Information: TOUJEO(R) subcutaneous injection, insulin glargine subcutaneous injection. sanofi-aventis (per manufacturer), Bridgewater, NJ, 2015. DailyMed
- Product Information: AMARYL(R) oral tablets, glimepiride oral tablets. Sanofi-Aventis U.S. LLC (per FDA), Bridgewater, NJ, 2013. DailyMed
- Product Information: AFREZZA(R) oral inhalation powder, insulin human oral inhalation powder. MannKind Corporation(TM) (per manufacturer), Danbury, CT, 2014. DailyMed
- Product Information: Zestril(R) oral tablets, lisinopril oral tablets. AstraZeneca Pharmaceuticals LP (per FDA), Wilmington, DE, 2014. DailyMed
- Hee Nam Y, Brensinger CM, Bilker WB, et al: Angiotensin-converting enzyme inhibitors used concomitantly with insulin secretagogues and the risk of serious hypoglycemia. Clin Pharmacol Ther 2022; 111(1):218-226. PubMed
Keep reading about Acarbose
Keep reading about Trandolapril
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist